| Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2123 | 2003 |
| Changing patterns of mortality across Europe in patients infected with HIV-1 A Mocroft, S Vella, TL Benfield, A Chiesi, V Miller, P Gargalianos, ... The Lancet 352 (9142), 1725-1730, 1998 | 1676 | 1998 |
| Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society–USA Panel CCJ Carpenter, MA Fischl, SM Hammer, MS Hirsch, DM Jacobsen, ... Jama 280 (1), 78-86, 1998 | 1624* | 1998 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1580 | 2018 |
| Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study Data Collection on Adverse Events of Anti-HIV Drugs Study Group Archives of internal medicine 166 (15), 1632-1641, 2006 | 1508 | 2006 |
| Antiretroviral therapy in adults: updated recommendations of the International AIDS Society–USA Panel CCJ Carpenter, DA Cooper, MA Fischl, JM Gatell, BG Gazzard, ... Jama 283 (3), 381-390, 2000 | 1379 | 2000 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1182 | 2008 |
| Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society–USA panel SM Hammer, MS Saag, M Schechter, JSG Montaner, RT Schooley, ... Jama 296 (7), 827-843, 2006 | 1137 | 2006 |
| Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society—USA Panel CCJ Carpenter, MA Fischl, SM Hammer, MS Hirsch, DM Jacobsen, ... Jama 277 (24), 1962-1969, 1997 | 1049 | 1997 |
| A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial JSG Montaner, P Reiss, D Cooper, S Vella, M Harris, B Conway, ... Jama 279 (12), 930-937, 1998 | 1011 | 1998 |
| Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel PG Yeni, SM Hammer, CCJ Carpenter, DA Cooper, MA Fischl, JM Gatell, ... Jama 288 (2), 222-235, 2002 | 987 | 2002 |
| Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society–USA Panel MS Hirsch, F Brun-Vézinet, TD Richard, SM Hammer, VA Johnson, ... Jama 283 (18), 2417-2426, 2000 | 814 | 2000 |
| Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort D Konopnicki, A Mocroft, S De Wit, F Antunes, B Ledergerber, C Katlama, ... Aids 19 (6), 593-601, 2005 | 751 | 2005 |
| Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel PG Yeni, SM Hammer, MS Hirsch, MS Saag, M Schechter, CCJ Carpenter, ... Jama 292 (2), 251-265, 2004 | 741 | 2004 |
| Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management MS Hirsch, B Conway, TD Richard, VA Johnson, F Brun-Vézinet, B Clotet, ... Jama 279 (24), 1984-1991, 1998 | 733 | 1998 |
| Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals JH Darbyshire The Lancet 348 (9023), 283-291, 1996 | 561 | 1996 |
| Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection GK Robbins, V De Gruttola, RW Shafer, LM Smeaton, SW Snyder, ... New England Journal of Medicine 349 (24), 2293-2303, 2003 | 477 | 2003 |
| Beyond viral suppression of HIV–the new quality of life frontier JV Lazarus, K Safreed-Harmon, SE Barton, D Costagliola, N Dedes, ... BMC medicine 14, 1-5, 2016 | 393 | 2016 |
| Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs C Katlama, SG Deeks, B Autran, J Martinez-Picado, J Van Lunzen, ... The Lancet 381 (9883), 2109-2117, 2013 | 378 | 2013 |
| Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission LG Bekker, G Alleyne, S Baral, J Cepeda, D Daskalakis, D Dowdy, ... The Lancet 392 (10144), 312-358, 2018 | 352 | 2018 |
Loredana SarmatiProfessore Ordinario Malattie Infettive, Dipartimento di Medicina dei Sistemi, Università Tor在 med.uniroma2.it 的电子邮件经过验证
